Please assess the completion status of the following clinical trial:

Trial Title: Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults incarcerated in NYC jails with known release date~* DSM-IV criteria for current opioid dependence~* No current agonist (methadone, buprenorphine) treatment~* Currently opioid free by history ('detoxed') and with a negative urine for all opioids~* General good health as determined by complete medical interview and physical examination~* Age 18-60 years.~Exclusion Criteria:~* History of liver failure, cirrhosis, or recent liver function test levels greater than three times normal~* Pregnancy, lactation, or planning conception~* Active medical illness that might make participation hazardous~* Untreated psychiatric disorder~* History of allergic reaction to naltrexone, PLG (polylactide co-glycolide), carboxymethylcellulose, or any other components of the diluent.~* Current chronic pain condition treated with opioids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Extended-release naltrexone (XR-NTX) (Type: ACTIVE_COMPARATOR): A single 380mg IM depot injection of XR-NTX in the week prior to release from jail. A second 380mg IM injection is offered to persons in the XR-NTX arm post-release and 4 weeks after the initial injection.
- Motivational Enhancement Counseling Only (Type: PLACEBO_COMPARATOR): The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.

Based on this trial design, predict the completion outcome and termination type (if applicable).